Literature DB >> 21434681

LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.

Jonathan Woodward1, Stephen J Kennel, Alan Stuckey, Dustin Osborne, Jonathan Wall, Adam J Rondinone, Robert F Standaert, Saed Mirzadeh.   

Abstract

Nanoscale materials have been envisioned as carriers for various therapeutic drugs, including radioisotopes. Inorganic nanoparticles (NPs) are particularly appealing vehicles for targeted radiotherapy because they can package several radioactive atoms into a single carrier and can potentially retain daughter radioisotopes produced by in vivo generators such as actinium-225 ((225)Ac, t(1/2) = 10 d). Decay of this radioisotope to stable bismuth-209 proceeds through a chain of short-lived daughters accompanied by the emission of four α-particles that release >27 MeV of energy. The challenge in realizing the enhanced cytotoxic potential of in vivo generators lies in retaining the daughter nuclei at the therapy site. When (225)Ac is attached to targeting agents via standard chelate conjugation methods, all of the daughter radionuclides are released after the initial α-decay occurs. In this work, (225)Ac was incorporated into lanthanum phosphate NPs to determine whether the radioisotope and its daughters would be retained within the dense mineral lattice. Further, the (225)Ac-doped NPs were conjugated to the monoclonal antibody mAb 201B, which targets mouse lung endothelium through the vasculature, to ascertain the targeting efficacy and in vivo retention of radioisotopes. Standard biodistribution techniques and microSPECT/CT imaging of (225)Ac as well as the daughter radioisotopes showed that the NPs accumulated rapidly in mouse lung after intravenous injection. By showing that excess, competing, uncoupled antibodies or NPs coupled to control mAbs are deposited primarily in the liver and spleen, specific targeting of NP-mAb 201B conjugates was demonstrated. Biodistribution analysis showed that ∼30% of the total injected dose of La((225)Ac)PO(4) NPs accumulated in mouse lungs 1 h postinjection, yielding a value of % ID/g >200. Furthermore, after 24 h, 80% of the (213)Bi daughter produced from (225)Ac decay was retained within the target organ and (213)Bi retention increased to ∼87% at 120 h. In vitro analyses, conducted over a 1 month interval, demonstrated that ∼50% of the daughters were retained within the La((225)Ac)PO(4) NPs at any point over that time frame. Although most of the γ-rays from radionuclides in the (225)Ac decay chain are too energetic to be captured efficiently by SPECT detectors, appropriate energy windows were found that provided dramatic microSPECT images of the NP distribution in vivo. We conclude that La((225)Ac)PO(4)-mAb 201B conjugates can be targeted efficiently to mouse lung while partially retaining daughter products and that targeting can be monitored by biodistribution techniques and microSPECT imaging.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21434681     DOI: 10.1021/bc100574f

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  19 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

2.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

Review 3.  Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals.

Authors:  Youngho Seo
Journal:  Nucl Med Mol Imaging       Date:  2019-02-18

Review 4.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

5.  Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.

Authors:  Markus Essler; Florian C Gärtner; Frauke Neff; Birgit Blechert; Reingard Senekowitsch-Schmidtke; Frank Bruchertseifer; Alfred Morgenstern; Christof Seidl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-12       Impact factor: 9.236

6.  The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides.

Authors:  N L Ackerman; E E Graves
Journal:  Phys Med Biol       Date:  2012-01-18       Impact factor: 3.609

Review 7.  Molecular targeted α-particle therapy for oncologic applications.

Authors:  Thaddeus J Wadas; Darpan N Pandya; Kiran Kumar Solingapuram Sai; Akiva Mintz
Journal:  AJR Am J Roentgenol       Date:  2014-08       Impact factor: 3.959

8.  Functionalized NaA nanozeolites labeled with 224,225Ra for targeted alpha therapy.

Authors:  Agata Piotrowska; Edyta Leszczuk; Frank Bruchertseifer; Alfred Morgenstern; Aleksander Bilewicz
Journal:  J Nanopart Res       Date:  2013-10-31       Impact factor: 2.253

Review 9.  Targeted and Nontargeted α-Particle Therapies.

Authors:  Michael R McDevitt; George Sgouros; Stavroula Sofou
Journal:  Annu Rev Biomed Eng       Date:  2018-01-18       Impact factor: 9.590

10.  Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy.

Authors:  Mark F McLaughlin; Jonathan Woodward; Rose A Boll; Jonathan S Wall; Adam J Rondinone; Stephen J Kennel; Saed Mirzadeh; J David Robertson
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.